Руководство по PE-22-28

PE-22-28 — это синтетический пептид, который блокирует калиевые каналы TREK-1. В отличие от СИОЗС, эффект которых наступает через недели, PE-22-28 напрямую влияет на каналы, повышая уровень серотонина за считанные дни в животных моделях.

TREK-1 channels are mechanosensitive potassium channels that hyperpolarize serotonergic neurons when open — reducing their firing rate and serotonin release. PE-22-28 blocks these channels, allowing serotonergic neurons to maintain higher tonic firing rates. This directly increases serotonin release in the hippocampus and prefrontal cortex without receptor desensitization or reuptake inhibition.

SSRIs require weeks to produce clinically meaningful serotonin increases because initial SERT blockade triggers auto-receptor feedback that reduces serotonin neuron firing. As 5-HT1A autoreceptors desensitize over weeks, the full antidepressant effect emerges. PE-22-28 bypasses this delay entirely — no autoreceptor desensitization is required because it increases serotonin through a different node in the circuit.

Like chronic SSRI treatment, PE-22-28 promotes adult hippocampal neurogenesis in animal studies — increasing BrdU-positive proliferating cells in the dentate gyrus subgranular zone. This neurogenic effect correlates with antidepressant behavioral outcomes in animal models and may underlie the longer-lasting mood regulation seen beyond the immediate serotonin effects of TREK-1 blockade.

Beyond depression models, PE-22-28 shows anxiolytic properties in open field and elevated plus maze tests. TREK-1 channels are also expressed in amygdala circuits that regulate fear and anxiety responses. PE-22-28's channel-blocking action in these regions appears to reduce amygdala hyperreactivity — complementing its serotonin-enhancing effects in depression circuits for a dual antidepressant-anxiolytic profile.

TREK-1 Channel Blockade: TREK-1 channels are mechanosensitive potassium channels that hyperpolarize serotonergic neurons when open — reducing their firing rate and serotonin release. PE-22-28 blocks these channels, allowing serotonergic neurons to maintain higher tonic firing rates. This directly increases serotonin release in the hippocampus and prefrontal cortex without receptor desensitization or reuptake inhibition.

Fast Serotonin Increase: SSRIs require weeks to produce clinically meaningful serotonin increases because initial SERT blockade triggers auto-receptor feedback that reduces serotonin neuron firing. As 5-HT1A autoreceptors desensitize over weeks, the full antidepressant effect emerges. PE-22-28 bypasses this delay entirely — no autoreceptor desensitization is required because it increases serotonin through a different node in the circuit.

Hippocampal Neurogenesis: Like chronic SSRI treatment, PE-22-28 promotes adult hippocampal neurogenesis in animal studies — increasing BrdU-positive proliferating cells in the dentate gyrus subgranular zone. This neurogenic effect correlates with antidepressant behavioral outcomes in animal models and may underlie the longer-lasting mood regulation seen beyond the immediate serotonin effects of TREK-1 blockade.

Anxiety Reduction: Beyond depression models, PE-22-28 shows anxiolytic properties in open field and elevated plus maze tests. TREK-1 channels are also expressed in amygdala circuits that regulate fear and anxiety responses. PE-22-28's channel-blocking action in these regions appears to reduce amygdala hyperreactivity — complementing its serotonin-enhancing effects in depression circuits for a dual antidepressant-anxiolytic profile.